首页 | 官方网站   微博 | 高级检索  
     

通管汤盆腔灌注对大鼠输卵管炎性阻塞性不孕模型病理及BCL-2、EGFR蛋白表达的影响
引用本文:胡晓玲,张晓春,江晓兰,彭清妹,傅贵平,王霞,张静芬.通管汤盆腔灌注对大鼠输卵管炎性阻塞性不孕模型病理及BCL-2、EGFR蛋白表达的影响[J].井冈山大学学报(自然科学版),2017(5):89-95.
作者姓名:胡晓玲  张晓春  江晓兰  彭清妹  傅贵平  王霞  张静芬
作者单位:井冈山大学基础医学与药学院, 江西, 吉安 343009,井冈山大学临床医学院, 江西, 吉安 343000,井冈山大学图书馆, 江西, 吉安 343009,井冈山大学临床医学院, 江西, 吉安 343000,井冈山大学临床医学院, 江西, 吉安 343000,井冈山大学基础医学与药学院, 江西, 吉安 343009,南昌市第三医院, 江西, 南昌 330009
基金项目:江西省科技支撑计划项目(20123BBG70211)
摘    要:目的研究自拟通管汤(简称通管汤)盆腔灌注对大鼠输卵管炎性阻塞的作用及机制。方法选用体重为(200±20)g,鼠龄8~12周的SD雌性大鼠130只,用混合菌制造大鼠输卵管炎性阻塞模型114只,随机分为正常对照组(A)、模型组(B)、兔耳风胶囊组(C)、通管汤组(低剂量组D_1、中剂量组D_2、高剂量组D_3)。采用输卵管通液观察输卵管通畅,HE染色观察输卵管组织形态学变化,免疫组化检测输卵管上皮细胞Bcl-2、EGFR的表达。结果 (1)治疗组输卵管通畅率D_3、D_2、C组与B、D_1组比较有非常显著性差异(P0.01);(2)D_3组与D_2、C组比较有较显著差异(P0.05);中高剂量治疗组(D_3、D_2)输卵管组织形态好转明显好于模型组(B)与低剂量组(D_1);治疗组输卵管上皮细胞Bcl-2、EGFR表达(P0.05-P0.01),差异有显著性,15 d与30 d比较无明显差异。结论通管汤高剂量组能缓解输卵管肿胀、减轻炎性细胞浸润、增加管腔纤毛数量和恢复输卵管通畅性;并通过下调Bcl-2、EGFR的过度表达,抑制输卵管上皮细胞凋亡和炎症反应,达到治疗输卵管炎性阻塞的作用。

关 键 词:通管汤  盆腔灌注  输卵管炎性阻塞  Bcl-2  EGFR
收稿时间:2017/7/12 0:00:00
修稿时间:2017/8/26 0:00:00

EFFECT OF THE TONGGUANTANG PELVIC CAVITY PERFUSION ON THE PATHOLOGY AND BCL-2, EGFR PROTEIN EXPRESSION OF THE FALLOPIAN TUBE INFLAMMATORY OBSTRUCTIVE INFERTILITY RAT MODEL
HU Xiao-ling,ZHANG Xiao-chun,JIANG Xiao-lan,PENG Qing-mei,FU Gui-ping,WANG Xia and ZHANG Jing-fen.EFFECT OF THE TONGGUANTANG PELVIC CAVITY PERFUSION ON THE PATHOLOGY AND BCL-2, EGFR PROTEIN EXPRESSION OF THE FALLOPIAN TUBE INFLAMMATORY OBSTRUCTIVE INFERTILITY RAT MODEL[J].Journal of Jinggangshan University(Natural Sciences Edition),2017(5):89-95.
Authors:HU Xiao-ling  ZHANG Xiao-chun  JIANG Xiao-lan  PENG Qing-mei  FU Gui-ping  WANG Xia and ZHANG Jing-fen
Affiliation:School of Medicine and Pharmacy, Jinggangshan University, Ji''an, Jiangxi 343009, China,School of Clinical Medicine, Jinggangshan University, Ji''an, Jiangxi 343000, China,Library of Jinggangshan University, Ji''an, Jiangxi 343009, China,School of Clinical Medicine, Jinggangshan University, Ji''an, Jiangxi 343000, China,School of Clinical Medicine, Jinggangshan University, Ji''an, Jiangxi 343000, China,School of Medicine and Pharmacy, Jinggangshan University, Ji''an, Jiangxi 343009, China and Third Hospital of Nangchang City, Nanchang, Jiangxi 330009, China
Abstract:Objective:To study the effect of the Tongguantang pelvic cavity perfusion on fallopian tube inflammatory obstruction. Methods:130 female rats with the weight of 200±20g and age from 8 to 12 weeks were selected, 114 fallopian tube inflammatory obstructive infertility rat models were made, which were randomly divided into control group (A), model group (B), Tuerfeng group (C), Tongguantang group (low dose D1, medium dose D2, high dose D3). The levels of obstruction of fallopian tube were observed by hydrotubation, The fallopian tube tubal histomorphology changes were observed by HE dyeing, Bcl-2, EGFR protein expressions of fallopian tubal epithelium cells were detected by immunohistochemistry detection. Results:There were significant differences in fallopian tubal patency rate between D3, D2, C and B, D1 (P<0.01), also between D3 and D2, C (P<0.05), D3''s The morphological improvements of fallopian tube in middle and high dose groups (D3, D2) were significantly better than that in B and D1; D3''s uterine tubal epithelium cell Bcl-2, EGFR expressions were lower than group B, C, D1 and D2 (P<0.01, P<0.05, P<0.01, P<0.05). Conclusion:High dose of Tongguantang can help relieve swollen uterine tubal epithelium, reduce inflammatory cellular infiltration, increase quantity of lumen cilium and regain free-flow of fallopian tube. Also through reducing the over-expression of Bc1-2 and EGFR, it can suppress the degradation and inflammation of uterine tubal epithelium cell, so to effectively treat inflammatory obstruction of fallopian tube.
Keywords:Tongguantang  pelvic cavity perfusion  FTIO (fallopian tube inflammatory obstructive)  BcL-2(B-cell lymphoma/leukemia-2)  EGFR (endothelial growth factor receptor)
本文献已被 CNKI 等数据库收录!
点击此处可从《井冈山大学学报(自然科学版)》浏览原始摘要信息
点击此处可从《井冈山大学学报(自然科学版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号